Shares of Ocera Therapeutics Inc. (NASDAQ:OCRX) saw strong trading volume on Thursday . 380,375 shares were traded during mid-day trading, an increase of 97% from the previous session’s volume of 193,093 shares.The stock last traded at $2.10 and had previously closed at $2.12.

Separately, Zacks Investment Research raised Ocera Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a report on Tuesday, August 9th.

The stock’s 50-day moving average price is $2.51 and its 200 day moving average price is $2.69. The firm’s market cap is $49.82 million.

Ocera Therapeutics (NASDAQ:OCRX) last posted its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.02. On average, analysts predict that Ocera Therapeutics Inc. will post ($1.34) EPS for the current year.

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.